Logo

Regulus Therapeutics Inc.

RGLS

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR tar… read more

Healthcare

Biotechnology

10 years

USD

Become a Premium user to unlock the Score details

Price

per share adjusted in USD

$8.16

Price

0.00%

$0.00

Market Cap

$564.950m

Small

Price/Earnings

-11.2x

-

3y Avg

-

5y Avg

Dividends

Ex-Dividend: -

0.00%

Yield

$0.00

Dividend

0.00%

Forward Dividend Growth

-

-

3y CAGR

-

5y CAGR
Payout

0.00%

-

Payout 3y

-

Payout 5y
Yield
Benchmark

Dividends

No items found.

Financials Overview

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$47.523m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$0.73

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$0.00

$74.826m

Assets

$5.798m

Liabilities

$1.401m

Debt
Debt to Assets

1.9%

-

Debt to EBITDA
Free Cash Flow

-$43.387m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics
No items found.
Press Releases
↑ TopSummaryPriceDividendsFinancialsPress Releases